Q2 FY27 earnings call · November 05, 2026
Marksans Pharma Q2 FY27 Earnings Call: Guides Rs. 4,000 Cr FY28 Revenue, Record Quarter Beats Margin Guidance
Listen to the earnings call
Quick summary
Marksans Pharma Ltd held its Q2 FY27 earnings call on November 04, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.
Record Quarter Beats Guidance, But Sequential PAT Slips
- Revenue of Rs.940 crore (+30.5% YoY, +11.8% QoQ) — a record quarter; total income rose 29.2% YoY to Rs.928 crore. Excluding the Clinic acquisition, underlying growth was ~25%.
- Record EBITDA of Rs.214 crore (+48.3% YoY) — margin expanded 274 bps to 22.8%, ahead of management's 20-21% guidance range (period unspecified).
- PAT of Rs.144 crore (+44.8% YoY; 15% net margin) — down sequentially from Rs.159 crore in Q1 FY 2026-2027 on higher D&A (amortisation of acquisition intangibles), lower other income and a 25.8% effective tax rate.
- H1 FY 2026-2027 revenue up 32.9% to Rs.1,781 crore — EBITDA up 74.7% to Rs.427 crore (24% margin); PAT up 92.5% to Rs.303 crore, aided by higher other income.
- Cash generation improved sharply — H1 operating cash flow of Rs.322 crore vs Rs.75 crore in H1 FY 2025-2026; cash conversion at 75.2% of EBITDA; free cash flow Rs.275 crore after Rs.46 crore capex.
- Balance sheet strengthened — net cash of Rs.1,095 crore at September-end; trailing 12-month ROCE improved to 24.7% (from 18.7%) and ROE to 18.6% (from 13.6%).
Europe and Australia Lead; US Steady; ROW Disrupted
- UK & Europe revenue of Rs.405 crore (+65% YoY; 43% of mix) — +49% excluding acquisitions; Clinic (Netherlands) contributed ~Rs.84 crore in H1 FY 2026-2027, with ABC and Marksans GmbH building the Germany platform.
- North America posted its highest-ever quarterly revenue of Rs.421 crore (+8.7% YoY; 44.8% of mix) — US price erosion in prescription products remains in single digits; management is "extremely optimistic" on the US market.
- Australia & New Zealand grew 64% YoY to ~Rs.101 crore (10.7% of mix) — driven by the branded prescription strategy under Nova, which markets 100% of the company's Australia sales.
- Rest of World at Rs.40 crore (1.5% of mix) — impacted by Middle East geopolitical disruptions and Red Sea logistics chaos affecting shipment timing; management characterised it as timing-related, not a change in underlying opportunity.
- US H1 softness attributed to seasonality and sentiment — management cited the cold-season (October-December) portfolio tilt plus consumer affordability pressure from inflation and crude, with medicines a lower priority than food and gas.
Gross Margin Peaking; API Prices and War the Swing Factors
- Gross margin at 58.5% (up 135 bps YoY, down from 59.1% in Q1) — management guided gross margin back to 55-56% for Q3 and Q4 FY 2026-2027 as the low-cost inventory benefit fades.
- Cost headwinds in Q2 — freight costs nearly doubled (~Rs.20 crore sequential rise in other expenses), employee costs up ~Rs.8 crore, and German operations incurred a couple of crores in startup costs.
- Elevated API prices (paracetamol, ibuprofen) seen cooling — management expects prices to ease "maybe in the next 30 days or so," contingent on crude prices falling; views elevated raw material costs as short-term and "not sustainable."
- War flagged as the key downside risk — management said if the war "goes from bad to worse," all projections go for a toss; margin upside beyond guidance is contingent on the war ending, with no formal guidance revision offered.
- Depreciation step-up of Rs.6-7 crore QoQ — CFO Jitendra Sharma attributed this to a Q2 FY 2026-2027 accounting change for intangibles (finite 10-year life) plus amortisation on ClinicU and ABC Now acquired intangibles; this level is the run-rate for Q3-Q4 FY 2026-2027.
- Lease liabilities rose Rs.120 crore in Q2 — driven by a new lease taken in the UK.
Rs.4,000 Crore in FY28; Long-Dated US, Australia and Europe Goals
- Rs.4,000 crore revenue guided for FY 2027-2028 — CMD Mark Saldanha said the company is trending close to Rs.1,000 crore per quarter (Q2 FY 2026-2027 run-rate) and can "very comfortably" hit the target next year; visibility also exists on a Rs.4,000 crore annualised mark for FY 2026-2027.
- Rs.5,000 crore within 3 years (by FY 2029-2030) — management is working towards this, and possibly doubling revenue to ~Rs.6,000 crore within 5 years (by FY 2031-2032).
- US order book targeted to rise from 225 to 300 crore within 3 years (by FY 2029-2030) — management expects 5-6 additional ANDA filings by March 2027 (FY 2026-2027) as part of a non-stop filing process.
- Australia expected to reach $100 million over the next 3 years (≈ by FY 2029-2030) — growth to be fueled by new launches, including nasal sprays currently outsourced but expected to be brought in-house (timeline unspecified).
- Europe target of Rs.1,000 crore top line in 5 years (≈ by FY 2031-2032) reaffirmed — management said the expanded European presence can create a meaningful growth channel beyond the UK over the next 3-5 years; Europe revenue streams are not factored into FY 2026-2027.
- UK growth called sustainable after a flat FY 2025-2026 — supported by the pipeline and visibility on upcoming approvals; revenue not expected to double overnight but to "grow significantly well."
- Volume-driven growth — CFO said a substantial part of H1 FY 2026-2027's 32.9% growth was volume-driven; OTC-RX mix steady at ~75% OTC / 25% RX; Q3 FY 2026-2027 is normally the stronger quarter, contingent on a strong winter.
M&A on Two Fronts; India Plant Acquisition Targeted in ~12 Months
- Two-front capital deployment — capex and M&A, with cash retained on the balance sheet to consummate acquisitions; management looks at a couple more M&As that may come across Europe (period unspecified), sized small to larger.
- India manufacturing acquisition in dialogue — management is in talks with two companies (nothing concrete yet) with a probable ~12-month timeline (i.e., during FY 2027-2028); CMD is evaluating assets across dosage forms, explicitly ruling out injectables, targeting forms where constraints are foreseen "maybe 2 years down the line" (~FY 2028-2029) — "there's always solid oral around it."
- Two-fold India capacity expansion toward 16 billion units per annum (period unspecified) — via new dosage blocks plus debottlenecking at the existing Teva plant infrastructure, and via plant acquisition.
- Oral solids capacity sufficient for the next 2-3 years — no current constraint, though management always wants additional capacity; ~98-99% of revenues come from own plants (US, UK, India) as of Q2 FY 2026-2027.
- More European deals hoped within 12 months (during FY 2027-2028) — management is exploring additional European M&As the Netherlands (Clinic) and Germany (ABC) platforms are country-specific and do not represent the whole of Europe.
- Access Healthcare (Dubai) "holding its own" — profitable and cash-generative despite the war, though revenue is extremely small relative to group turnover; management is working to increase its product pipeline ~10x (period unspecified). No Middle East acquisitions planned given the geopolitical scenario.
- Buyback remains an option — management has discussed it and will continue evaluating; a possibility if nothing else is happening on the capital deployment front (period unspecified).
FY27 Margin Guided Range-Bound; Dividend Unfinalised
- FY 2026-2027 EBITDA margin guided range-bound at 21-22% — in line with the Q2 level; the range-bound outlook reflects crude-oil-driven input cost inflation requiring replacement inventory at higher cost as low-cost stocks deplete.
- Q2 margin of 23% (per the analyst's framing) ran ahead of the ~21% full-year FY 2026-2027 guidance — asked if FY 2026-2027 margins could exceed ~21%, MD Mark Saldanha said it is "always a possibility" but contingent on the war ending, quipping one would have to "call the president and call off the war."
- ROW recovery conditional — management hopes to be back on track by end of FY 2026-2027; a quarterly run rate of Rs.20-25 crore is "doable" towards the exit of FY27 (FY 2026-2027), conditional on geopolitical easing; management declined to predict the war's duration, saying it has no crystal ball.
- Dividend policy for FY 2026-2027 not yet finalised — CMD said it still needs to be evaluated given multiple priorities; CFO Jitendra Sharma indicated it will "broadly" follow the historical practice of distributing one-third of free cash flow as dividend.
- H2 PAT seasonality not reaffirmed — on whether H2 FY 2026-2027 PAT will exceed H1 (the historical pattern), management did not explicitly reaffirm the trend; FY 2026-2027 PAT expected in line with expectations aside from taxation and depreciation provisions.
- No committed major capex cycle for FY 2027-2028 — management described its capex outlook as longer-term rather than immediate, with active dialogue on both adding a manufacturing block and acquiring a plant.
Ask about this
Ask Cofacto a question about this call. Answers cite filings and company data.
Companies on this page
Related
- Marksans Pharma Ltd Q2 FY27 Results Analysis: EBITDA Surges 48%, Acquisitions Drive 39.5% of PATResults analysis
- Marksans Pharma Limited (MARKSANS) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To WatchPreview
- Marksans Pharma Q1 FY27 Earnings Call: Peak EBITDA Margin of 25.3%, Maintains 20-21% EBITDA GuidanceQ1 FY2026-2027 Earnings Call
Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.